Fusen Pharm (01652): "Metformin Glipizide Tablet (I)" approved for market listing.

FUSEN PHARM (01652) announced that the company's research and development of "Metformin Empagliflozin Tablets (I)" has been approved by the China National Medical Products Administration for marketing, and is approved for the treatment of the following diseases: this product, in combination with diet control and exercise, is suitable for adult patients with type 2 diabetes who are currently being treated with empagliflozin and metformin hydrochloride, to improve blood sugar control in these patients. "Metformin Empagliflozin Tablets (I)" is a compound preparation composed of metformin hydrochloride and empagliflozin. The pharmacological actions are as follows: metformin can reduce hepatic glucose production, inhibit intestinal absorption of glucose, and increase the uptake and utilization of glucose by peripheral tissues, thereby increasing insulin sensitivity by increasing peripheral glucose uptake and utilization. Empagliflozin is an SGLT2 inhibitor that reduces renal glucose reabsorption, lowers the renal glucose threshold, promotes the excretion of glucose in the urine. The two have a synergistic effect in terms of mechanism, and compared with single-component preparations, they have a better hypoglycemic effect. The Board of Directors believes that Metformin Empagliflozin Tablets (I) is another important product for the company, further enriching the company's product pipeline in the field of diabetes treatment. This product will provide more treatment options for a large number of diabetes patients.